Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that following review by the Center for Drug Evaluation...
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals. The proposed indications...
HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights: Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period Regimen I...
Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help
Weekly updates from the National Comprehensive Cancer Network share every time a change is made to evidence-based, expert consensus-driven guidelines for cancer prevention, screening, treatment, and supportive care. PLYMOUTH MEETING, Pa., May 27, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—the nonprofit alliance of leading cancer centers responsible for essential NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)...
IMG Shares 2026 Summer Travel Insights: Higher Spending and Longer Trips
IMG reviewed the travel itineraries of more than 30,000 of its members with upcoming travel plans between June 1st and August 31st of 2026 to determine notable travel trends this summer. INDIANAPOLIS, May 27, 2026 /PRNewswire/ -- IMG (International Medical Group) has completed its annual review of summer travel data...
Metabolon Expands Global Access to Metabolomics with the Metabolon Verus™ Metabolomics Profiling Kit
Democratizing metabolomics for researchers worldwide, the new kit brings Metabolon's analytically rigorous, scalable metabolomics into workflows designed for integrated biological insights MORRISVILLE, N.C., May 27, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine...
SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies
SHANGHAI, May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in Cell with Professor Dan Li's team at the Bio-X Institute of Shanghai Jiao Tong University. The study, titled "TPPP/p25 amyloid seeding activity as a specific biomarker for multiple system...
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, Associate Director of Business Development at Viva Biotech, the roundtable featured Dr. Bing Xia, Vice President...
Sisram Medical Investor Day Key Takeaways
Advancing Global Medical Aesthetics Strategy and Unlocking Wellness Platform Value HONG KONG, May 27, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today announced that its Investor Day was successfully held on May 21 at the Shanghai Bund Finance Center (BFC). Under the theme of "Gathering...
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII‑179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study demonstrated that...
